Form 4: Adaptive Biotechnologies Director Boosts Stake

Adaptive Biotechnologies Corp. Director Robert Hershberg acquired 15,625 shares of common stock, increasing his beneficial ownership.

Summary

• Robert Hershberg, a Director of Adaptive Biotechnologies Corp. (ADPT), acquired 15,625 shares of common stock.
• The transaction occurred on March 4, 2026, with a reported price of $0 per share, indicating a grant or award rather than a market purchase.
• Following this transaction, Robert Hershberg beneficially owns a total of 62,347 shares of Adaptive Biotechnologies Corp. common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. A director increasing their stake, even via a grant, suggests confidence in the company's trajectory and aligns their interests with shareholders.

Positives

• A Director increasing their stake in the company, even through a grant, generally signals confidence in the company's future prospects and aligns management interests with shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly by directors, are often interpreted by the market as a positive signal, suggesting that those closest to the company believe in its future performance. This aligns with broader market trends where insider confidence can influence investor sentiment.

Related Party Transactions

• The acquisition of 15,625 shares of common stock by Director Robert Hershberg is a related party transaction.

Stakeholder Impact

• Shareholders may view this transaction as a positive indicator of insider confidence in the company's future, potentially bolstering investor sentiment.

Key Dates

Recommendation

The acquisition of shares by a director, even if a grant at a $0 price, generally signals management's belief in the company's long-term value. While not a direct cash purchase, it aligns the director's interests with shareholders, providing a modest positive signal for current holders, warranting a 'hold' rather than a 'strong buy' based solely on this transaction.

Keywords

Adaptive Biotechnologies, ADPT, Insider Transaction, Form 4, Director Stock Acquisition, Common Stock, Robert Hershberg, Corporate Governance